hydroxychloroquine has been researched along with Heart Failure in 30 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the relationship between the use of hydroxychloroquine (HCQ) and risk of developing heart failure (HF) in rheumatoid arthritis (RA)." | 8.02 | Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis. ( Achenbach, SJ; Crowson, CS; Kurmann, RD; Mankad, R; Myasoedova, E; Shahin, YE; Sorour, AA, 2021) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 6.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| "Hydroxychloroquine is a disease-modifying antirheumatic drug used for various rheumatological conditions." | 5.91 | Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. ( Dalia, T; Malhotra, A; Pathak, MA; Vidic, A, 2023) |
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "A patient with chronic systemic Weber-Christian disease who was treated with hydroxychloroquine developed cardiac dilatation with congestive heart failure." | 4.78 | Cardiac manifestations of Weber-Christian disease: report and review of the literature. ( Cupps, TR; Ferrans, VJ; Fox, LM; Lemley, DE; Satler, L, 1991) |
| "To examine the relationship between the use of hydroxychloroquine (HCQ) and risk of developing heart failure (HF) in rheumatoid arthritis (RA)." | 4.02 | Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis. ( Achenbach, SJ; Crowson, CS; Kurmann, RD; Mankad, R; Myasoedova, E; Shahin, YE; Sorour, AA, 2021) |
| "The purpose of this study was to investigate the propensity of hydroxychloroquine (HCQ) to cause bradycardia." | 3.81 | Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. ( Bub, G; Burton, RA; Capel, RA; Channon, K; Douglas, G; Herring, N; Kalla, M; Mirams, GR; Paterson, DJ; Terrar, DA; Yavari, A, 2015) |
| " Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage." | 2.82 | Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ( Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | 2.72 | Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "Hydroxychloroquine is a disease-modifying antirheumatic drug used for various rheumatological conditions." | 1.91 | Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. ( Dalia, T; Malhotra, A; Pathak, MA; Vidic, A, 2023) |
| "Mucormycosis is an invasive fungal infection (IFI) due to several species of saprophytic fungi, occurring in patients with underlying co-morbidities (including organ transplantation)." | 1.62 | Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. ( Berlinrut, I; Chang, KM; Khatri, A; Wallach, F, 2021) |
| " For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response." | 1.56 | It is time to drop hydroxychloroquine from our COVID-19 armamentarium. ( Kashour, T; Tleyjeh, IM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 4 (13.33) | 24.3611 |
| 2020's | 24 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pérez-Belmonte, LM | 1 |
| Sanz-Cánovas, J | 1 |
| Salinas, A | 1 |
| Fornie, IS | 1 |
| Méndez-Bailón, M | 1 |
| Gómez-Huelgas, R | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Singh, M | 1 |
| Smolenkova, I | 1 |
| Zheng, Y | 1 |
| Pushpakumar, S | 1 |
| Tyagi, SC | 1 |
| Gagnon, LR | 1 |
| Sadasivan, C | 1 |
| Yogasundaram, H | 1 |
| Oudit, GY | 1 |
| Jimenez, AL | 1 |
| Valle, A | 1 |
| Mustehsan, MH | 1 |
| Wang, S | 1 |
| Law, J | 1 |
| Guerrero, MS | 1 |
| Mowrey, WB | 1 |
| Horton, DB | 1 |
| Briceno, D | 1 |
| Broder, A | 1 |
| Jiang, RJ | 1 |
| Jia, J | 1 |
| Du, Y | 1 |
| Zhang, HS | 1 |
| Malhotra, A | 1 |
| Pathak, MA | 1 |
| Dalia, T | 1 |
| Vidic, A | 1 |
| Mathies, D | 1 |
| Rauschning, D | 1 |
| Wagner, U | 1 |
| Mueller, F | 1 |
| Maibaum, M | 1 |
| Binnemann, C | 1 |
| Waldeck, S | 1 |
| Thinnes, K | 1 |
| Braun, M | 1 |
| Schmidbauer, W | 1 |
| Hagen, RM | 1 |
| Bickel, C | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 2 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 2 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 2 |
| Masoumi, A | 1 |
| Wille, F | 1 |
| Birkmeier, S | 1 |
| Tiemann, K | 1 |
| Lewalter, T | 1 |
| Klingel, K | 1 |
| Rabe, C | 1 |
| Sick, P | 1 |
| Figliozzi, S | 1 |
| Rizzo, S | 1 |
| De Gaspari, M | 1 |
| Tarantini, G | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| García-Saavedra, MB | 1 |
| Rosales-Gutiérrez, RR | 1 |
| Valverde, E | 1 |
| Chumbes-Aguirre, M | 1 |
| Alvarado, R | 1 |
| Polo, R | 1 |
| Azañero, R | 1 |
| Chávez, C | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Naka, Y | 1 |
| Geisler, BP | 1 |
| Kingsley, TC | 1 |
| Izmirly, PM | 1 |
| Costedoat-Chalumeau, N | 1 |
| Roswell, RO | 1 |
| Kashour, T | 1 |
| Tleyjeh, IM | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Lee, KH | 1 |
| Kim, JS | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Lee, S | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Dragioti, E | 1 |
| Li, H | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Sorour, AA | 1 |
| Kurmann, RD | 1 |
| Shahin, YE | 1 |
| Crowson, CS | 1 |
| Achenbach, SJ | 1 |
| Mankad, R | 1 |
| Myasoedova, E | 1 |
| O'Connell, TF | 1 |
| Bradley, CJ | 1 |
| Abbas, AE | 1 |
| Williamson, BD | 1 |
| Rusia, A | 1 |
| Tawney, AM | 1 |
| Gaines, R | 1 |
| Schott, J | 1 |
| Dmitrienko, A | 1 |
| Haines, DE | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Khatri, A | 1 |
| Chang, KM | 1 |
| Berlinrut, I | 1 |
| Wallach, F | 1 |
| Chen, J | 1 |
| Norling, LV | 1 |
| Cooper, D | 1 |
| Capel, RA | 1 |
| Herring, N | 1 |
| Kalla, M | 1 |
| Yavari, A | 1 |
| Mirams, GR | 1 |
| Douglas, G | 1 |
| Bub, G | 1 |
| Channon, K | 1 |
| Paterson, DJ | 1 |
| Terrar, DA | 1 |
| Burton, RA | 1 |
| Kwon, JB | 1 |
| Kleiner, A | 1 |
| Ishida, K | 1 |
| Godown, J | 1 |
| Ciafaloni, E | 1 |
| Looney, RJ | 1 |
| Muthukrishnan, P | 1 |
| Roukoz, H | 1 |
| Grafton, G | 1 |
| Jessurun, J | 1 |
| Colvin-Adams, M | 1 |
| Newton-Cheh, C | 1 |
| Lin, AE | 1 |
| Baggish, AL | 1 |
| Wang, H | 1 |
| Ka, MM | 1 |
| Leye, A | 1 |
| Dangou, JM | 1 |
| Ka, EF | 1 |
| Diallo, S | 1 |
| Mbengue, M | 1 |
| Ndongo, S | 1 |
| Diop, TM | 1 |
| Lemley, DE | 1 |
| Ferrans, VJ | 1 |
| Fox, LM | 1 |
| Satler, L | 1 |
| Cupps, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxychloroquine and Heart Failure
| Article | Year |
|---|---|
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Heart Failure; Humans; Hydroxychloroquine; Pan | 2022 |
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
[Cardiovascular implications of SARS-CoV-2 infection: A literature review].
Topics: Acute Coronary Syndrome; Algorithms; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme | 2020 |
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheuma | 2021 |
Cardiac manifestations of Weber-Christian disease: report and review of the literature.
Topics: Adult; Aged; Female; Heart Failure; Humans; Hydroxychloroquine; Male; Middle Aged; Myocardium; Panni | 1991 |
22 other studies available for hydroxychloroquine and Heart Failure
| Article | Year |
|---|---|
Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study.
Topics: Adrenal Cortex Hormones; Aged; COVID-19; COVID-19 Drug Treatment; Critical Care; Female; Heart Failu | 2021 |
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.
Topics: Animals; Blood; Blood Physiological Phenomena; Cardiomegaly; Cardiovascular Diseases; Cardiovascular | 2021 |
Association of Hydroxychloroquine Dose With Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus.
Topics: Antirheumatic Agents; Heart Failure; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Stro | 2023 |
Sinus bradycardia and heart failure induced by short-term use of low-dose hydroxychloroquine: A case report.
Topics: Bradycardia; Heart Failure; Humans; Hydroxychloroquine | 2023 |
Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Cardiac Catheterization; Cardiomyopathies; Female; Heart Failure; Hum | 2023 |
A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant.
Topics: Aged; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
[Proximal myopathy and fulminant heart failure in a 57 year-old female patient with lupus erythematosus].
Topics: Biopsy; Cardiomyopathies; Echocardiography; Fatal Outcome; Female; Heart; Heart Failure; Humans; Hyd | 2020 |
End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
Topics: COVID-19; Heart Failure; Humans; Hydroxychloroquine | 2021 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Hydroxychloroquine Toxicity: Concurrent Complete Heart Block and Severe Left Ventricular Systolic Dysfunction. A Clinical Image.
Topics: Heart Block; Heart Failure; Humans; Hydroxychloroquine; Stroke Volume; Ventricular Dysfunction, Left | 2021 |
It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Bradycardia; COVID-19 Drug Treatment; | 2020 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Heart Failure; Humans; Hydroxychloroquine | 2021 |
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Body Mass Index; Comorbid | 2021 |
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature.
Topics: Aged; Anti-Infective Agents; Bacteremia; Catheter-Related Infections; Coinfection; Combined Modality | 2021 |
Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.
Topics: Action Potentials; Animals; Bradycardia; Disease Models, Animal; Electrophysiological Phenomena; Enz | 2015 |
Hydroxychloroquine-induced myopathy.
Topics: Aged; Antirheumatic Agents; Apnea; Female; Heart Failure; Humans; Hydroxychloroquine; Muscular Disea | 2010 |
Hydroxychloroquine-induced cardiomyopathy: a case report.
Topics: Biopsy; Cardiac Resynchronization Therapy; Cardiomyopathies; Cardiovascular Agents; Defibrillators, | 2011 |
Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure.
Topics: Antirheumatic Agents; Biomarkers; Cardiomyopathies; Diagnosis, Differential; Echocardiography; Elect | 2011 |
[Multicentric reticulohistiocytosis with a 20-year follow-up ].
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Arthritis; Biopsy; Drug Therapy, Combination; | 2002 |